<DOC>
	<DOCNO>NCT01135069</DOCNO>
	<brief_summary>The objective ass clinical bioequivalence 0.1 % Retin-A Micro® Gel Spear Pharmaceutical 's generic 0.1 % Tretinoin Microsphere Gel placebo arm .</brief_summary>
	<brief_title>Bioequivalence Study Generic Tretinoin 0.1 % Microsphere Gel , 0.1 % Retin-A Micro® Placebo</brief_title>
	<detailed_description>Not require</detailed_description>
	<mesh_term>Tretinoin</mesh_term>
	<criteria>Normal , healthy male female child adult Written verbal inform consent must obtain . Patients age 12 17 ( inclusive ) must sign assent study parent legal guardian must sign informed consent . Women childbearing potential must nonpregnant nonnursing , must willing avoid pregnancy course study menstrual cycle follow completion participation study . Able refrain use topical acne medication antibiotics treatment period . Considered reliable capable understanding responsibility role study . Significant history clinical evidence autoimmune , cardiovascular , gastrointestinal , hematological , hepatic , neurological , pancreatic , renal disease . Abnormal preexist skin condition might affect normal course acne vulgaris ( e.g. , eczema , psoriasis , albinism , chronic vesiculobullous disorder ) . Use topical acne therapy two week period prior study initiation . Use systemic retinoid treatment within six month prior study initiation . Pregnant breastfeeding . Serious psychological illness . Participation clinical research study 30 day period precede study initiation .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>